Irvine, CA— Algae Health Sciences, Inc., a subsidiary of BGG, announced in a press release the results of a clinical trial published by the American College of Sports Nutrition, studying the firm’s AstaZine Natural Astaxanthin on runners (1). Results showed heart rate was reduced by 10% during long-distance running in subjects taking the astaxanthin. “We found a very novel effect of natural astaxanthin to improve overall cardiovascular function,” said Shawn Talbott, Ph.D., the study’s lead researcher.  “The subjects in this study were able to perform the same amount of ‘work’—but at lower cardiovascular ‘strain’ after supplementing with astaxanthin.”

“The implications of this study for athletes as well as potential benefits for anyone concerned with cardiovascular health are immense,” states BGG’s CEO, Yanmei Li, Ph.D.  “We plan to publish this result in conjunction with some other exciting clinical results in a strong peer-reviewed journal later this year.”

The product line has also earned self-affirmed GRAS status in addition to the first Astaxanthin new dietary ingredient (NDI) over 12 mg per day accepted by the U.S. Food and Drug Administration (FDA), two Novel Food Approvals in the EU for different Astaxanthin extraction methods, 239 Structure/Function claims submitted to FDA without objection as well as first Certified Organic Astaxanthin product with their 5% powder.

  1. Talbott, J., Hantla, D., Talbott, S. (2017).  “Effect of Astaxanthin Supplementation on  Cardiorespiratory Function in Runners.”  Journal of American College of Sports Medicine Vol. 49, No. 5, S705, June 2, 2017.